(Q53325822)

13 May 2018

title

8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. (English)

1 reference

13 May 2018

1 reference

1

1 reference

13 May 2018

Fernanda Borges

6

1 reference

13 May 2018

Eugenio Uriarte

7

1 reference

13 May 2018

Maria J. Matos

object named as

Maria J Matos

2

0 references

author name string

Giulio Ferino

3

1 reference

13 May 2018

Enzo Cadoni

4

1 reference

13 May 2018

Reyes Laguna

5

1 reference

13 May 2018

Lourdes Santana

8

1 reference

13 May 2018

publication date

27 January 2012

1 reference

13 May 2018

published in

ChemMedChem

1 reference

13 May 2018

volume

7

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

464-470

1 reference

13 May 2018

Enzymology of monoamine oxidase

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Tissue distribution of human monoamine oxidase A and B mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Biochemistry and genetics of monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Monoamine oxidase-B inhibition in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Oxidative stress and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Clinical pharmacology of MAO inhibitors: safety and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Neuroprotective effect of osthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B ∥

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Chalcones: a valid scaffold for monoamine oxidases inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, R

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

inferred from DOI database lookup

7 January 2021

based on heuristic

Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

inferred from DOI database lookup

7 January 2021

based on heuristic

Regioselective Synthesis of Bromo-Substituted 3-Arylcoumarins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100538

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMDC.201100538

1 reference

13 May 2018

1 reference

13 May 2018